Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,429 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: opiates Clear all

Conditions: Chronic Low Back Pain
Interventions: hydrocodone/acetaminophen extended release, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 17
States / cities: Tucson, Arizona • Anaheim, California • Burbank, California + 14 more

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Severe Traumatic Brain Injury, Intracranial Hypertension, Intracranial Hemorrhage, Hypertensive
Interventions: Ketamine with propofol, Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam; Drug · Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions: Buprenorphine Buccal Film [Belbuca]; Drug
Lead sponsor: Natasha Archer; Other
Eligibility: 12 Years to 22 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Procedural Pain, Buprenorphine, Adjuvants, Anesthesia, Dilation and Evacuation, Analgesics
Interventions: Buprenorphine 0.15 MG, Lidocaine 1% Injectable Solution; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Locally Advanced Head and Neck Cancer
Interventions: Xtampza ER; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Impulse Control Disorder, Parkinson Disease
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Postoperative, Premature Infant, Opioid Use
Interventions: Acetaminophen, Saline; Drug
Lead sponsor: St. Louis University; Other
Eligibility: Up to 1 Month
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Opioid-Related Disorders
Interventions: LAAM; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Drug Overdose, Opioid Withdrawal, Opioid-use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Aging
Interventions: low-dose naltrexone; Drug
Lead sponsor: AgelessRx; Industry
Eligibility: 18 Years to 120 Years
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: 4.5 mg Naltrexone, Naltrexone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 86 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Dependence
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Pyromania
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 16 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Conscious Sedation
Interventions: Gabapentin, Standard sedation regimen; Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: ACL Surgery, Pain Management
Interventions: Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pain
Interventions: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more

Conditions: Cocaine Abuse, Cocaine Dependence, Opiate Dependence, Alcohol Dependence, Substance Abuse
Interventions: modafinil, d-amphetamine, L-Dopa, Naltrexone; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Dextromethorphan, Healthy Adult Volunteers
Interventions: Isavuconazole, dextromethorphan; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Treatment of Menopausal Hot Flashes
Interventions: Standard Dose Kappa Agonist, Half Dose Kappa Agonist, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: darunavir/ritonavir, lopinavir/ritonavir, Midazolam, Dextromethorphan, Flurbiprofen, GSK2248761; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Dependency
Interventions: Psychosocial treatment plus Suboxone pharmacotherapy; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 15 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain Management
Interventions: Tramadol, Morphine, Placebo; Drug · Other
Lead sponsor: Avenue Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Pasadena, California • Houston, Texas • San Antonio, Texas

Search by objective public record fields.

Phase 2 Chronic Low Back Pain Study

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

Ketamine for Sedation in Severe Traumatic Brain Injury

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion

Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer

Naltrexone for Impulse Control Disorders in Parkinson's Disease

Postoperative Pain Control & Relief in Neonates

Feasibility Study of Take-Home LAAM Medication - 3

Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal

The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone

Naltrexone in the Treatment of Pyromania

Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Efficacy of Methylprednisolone for Pain Control After ACL Repair

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

Substance Abuse Pre-Treatment Screening Study

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects

Effects of a Kappa Agonist on Hot Flashes in Menopausal Women

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

Optimizing Outcomes Using Suboxone for Opiate Dependence

Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty